Your browser is no longer supported. Please, upgrade your browser.
Settings
DEPO Depomed, Inc. daily Stock Chart
DEPO [NASD]
Depomed, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own0.20% Shs Outstand61.58M Perf Week-8.71%
Market Cap1.14B Forward P/E14.55 EPS next Y1.28 Insider Trans-27.85% Shs Float60.87M Perf Month-17.96%
Income-75.00M PEG- EPS next Q0.37 Inst Own- Short Float19.45% Perf Quarter-9.95%
Sales443.20M P/S2.58 EPS this Y-161.40% Inst Trans-2.65% Short Ratio6.58 Perf Half Y-7.99%
Book/sh4.73 P/B3.92 EPS next Y22.48% ROA-5.80% Target Price24.27 Perf Year-4.04%
Cash/sh2.21 P/C8.40 EPS next 5Y16.00% ROE-25.00% 52W Range12.25 - 27.02 Perf YTD2.32%
Dividend- P/FCF13.81 EPS past 5Y78.69% ROI-0.30% 52W High-29.61% Beta1.42
Dividend %- Quick Ratio1.20 Sales past 5Y33.50% Gross Margin80.60% 52W Low55.27% ATR1.03
Employees494 Current Ratio1.20 Sales Q/Q5.30% Oper. Margin-4.50% RSI (14)31.89 Volatility4.45% 5.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.40% Profit Margin-16.90% Rel Volume0.47 Prev Close18.55
ShortableYes LT Debt/Eq2.49 EarningsNov 07 AMC Payout- Avg Volume1.80M Price19.02
Recom2.30 SMA20-7.35% SMA50-16.30% SMA200-2.54% Volume673,359 Change2.53%
Nov-09-16Upgrade Mizuho Neutral → Buy $24
Nov-08-16Downgrade Cantor Fitzgerald Buy → Hold
Oct-04-16Downgrade Mizuho Buy → Neutral $27
Sep-19-16Reiterated Mizuho Buy $23 → $27
Jul-27-16Downgrade Piper Jaffray Overweight → Neutral
Jul-07-16Downgrade UBS Buy → Neutral $20
May-27-16Reiterated Mizuho Buy $19 → $23
May-09-16Upgrade Mizuho Neutral → Buy $19
Apr-11-16Reiterated Mizuho Neutral $14 → $18
Mar-24-16Reiterated Mizuho Neutral $16 → $14
Mar-24-16Initiated Northland Capital Outperform
Mar-10-16Initiated Leerink Partners Outperform $21
Feb-25-16Reiterated Mizuho Buy $19 → $16
Feb-24-16Reiterated WallachBeth Buy $33 → $27
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $26 → $24
Feb-08-16Initiated Piper Jaffray Overweight
Jan-07-16Initiated Mizuho Neutral $19
Dec-03-15Resumed Morgan Stanley Equal-Weight $21
Nov-11-15Upgrade WallachBeth Hold → Buy $33
Nov-11-15Reiterated ROTH Capital Buy $21 → $24
Dec-02-16 08:40AM  Is Depomed Inc (DEPO) A Good Stock To Buy? at Insider Monkey
Dec-01-16 11:35AM  ETFs with exposure to Depomed, Inc. : December 1, 2016
07:45AM  What's behind put trade in Depomed
Nov-22-16 04:01PM  Depomed to Present at the Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-18-16 01:05PM  ETFs with exposure to Depomed, Inc. : November 18, 2016
Nov-17-16 01:04PM  DEPOMED INC Financials
11:18AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016
08:15AM  Blog Coverage Cumberland Pharma Bags Exclusive Rights for Europe Based Nordic Group Injectable Methotrexate Product Line for the US Market Accesswire
06:42AM  Executive Edge: Google Earth in VR
Nov-16-16 08:00AM  Depomed Named to Deloitte's Technology Fast 500 List of Fastest Growing Companies in North America GlobeNewswire
Nov-11-16 03:15PM  Depomed CEO has fended off multiple takeovers with strategic thinking at bizjournals.com
08:58AM  Are Investors Right To Be Bullish On Deckers Outdoor Corp (DECK), Tower Semiconductor Ltd. (TSEM), More? at Insider Monkey
Nov-09-16 05:57AM  DepoMed upgraded by Mizuho
Nov-08-16 05:06PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers -16.95%
03:19PM  Why Depomed Inc.'s Shares Are Crashing 18.9% Today at Motley Fool
11:54AM  Depomed Reports Dip in Earnings, Reduces Revenue Guidance
10:25AM  Depomed Tumbles on Missed Earnings
09:29AM  Stocks to Watch: Valeant, CVS Health, Hertz Global at The Wall Street Journal
08:15AM  Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More
06:16AM  Trade sees cap on Depomed gains
Nov-07-16 06:17PM  Edited Transcript of DEPO earnings conference call or presentation 7-Nov-16 9:30pm GMT
05:31PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:48PM  Depomed reports 3Q loss
04:31PM  Depomed plummets after disappointing sales of painkillers at MarketWatch
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:00PM  Depomed Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 Depomed Inc Earnings Release - After Market Close
Nov-04-16 08:15AM  Blog Coverage MEI Pharma and Helsinn Group Announced Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accesswire
08:00AM  Depomed Announces New CAMBIA® Formulation GlobeNewswire
01:17AM  Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns at Insider Monkey
Nov-03-16 12:39PM  Heres Why Dynegy, Lattice Semiconductor, and Three Other Stocks Are in Spotlight Today at Insider Monkey
Oct-31-16 04:00PM  Depomed to Report Third Quarter Fiscal Year 2016 Financial Results on Monday, November 7, 2016 GlobeNewswire
08:34AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : October 31, 2016
Oct-25-16 04:08PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-19-16 05:52PM  East Bay drug maker wards off hedge fund challenge with a price at bizjournals.com
06:03AM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers
Oct-18-16 10:54AM  Why Visa, Johnson and Johnson, Pfizer, and Two Other Stocks Are in Spotlight Today at Insider Monkey
10:45AM  Is Settling With an Activist Investor Supposed to Be Bad for Shareholders?
Oct-17-16 06:33PM  [$$] Depomed to Add Starboard Nominees at The Wall Street Journal
06:33PM  Depomed agrees temporary truce with Starboard in proxy fight
05:43PM  Starboard DepoMed Director Deal Bolsters Sale Prospects
04:50PM  Starboard drops its bid to oust Depomed's board
04:00PM  Depomed and Starboard Announce Settlement Agreement GlobeNewswire
Oct-07-16 04:33PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-04-16 03:49PM  Drug Win for Depomed Could Be Hurdle for Starboard
Oct-02-16 08:01AM  Why Diamondback Energy, Depomed, Las Vegas Sands and More Are Trending at Insider Monkey
Oct-01-16 07:51PM  East Bay drug company thwarts generics' grab, but fight's not over at bizjournals.com
Sep-30-16 05:40PM  [$$] Depomed Gets Favorable Nucynta Patent Decision at The Wall Street Journal
05:16PM  Depomed wins Nucynta patent dispute Reuters
04:56PM  Depomed gets favorable patent ruling; stock up 3% in extended trading at CNBC
04:39PM  Depomed fends off Allergan's attempt at generic painkiller at MarketWatch
04:15PM  Depomed (DEPO) Closed Higher on Favorable Patent Ruling
03:55PM  Depomed Prevails in NUCYNTA Franchise ANDA Litigation Providing Market Exclusivity Until December 2025 GlobeNewswire
Sep-22-16 03:40PM  How Much Could DepoMed Fetch in a Deal? at Motley Fool
11:09AM  Depomed Inc (DEPO): Starboard Value LP Schedules Special Meeting of Shareholders at Insider Monkey
Sep-20-16 09:59AM  Report: Depomed Is Attempting to Sell Itself at Investopedia
Sep-19-16 01:33PM  [$$] Depomed to Hold Nov. 15 Shareholder Meeting at The Wall Street Journal
11:34AM  Arbor and Purdue Seen as Likely Bidders for DepoMed
10:47AM  Heres Why These Five Stocks Are Trending on Monday at Insider Monkey
08:21AM  Starboard sets date for special meeting of Depomed shareholders Reuters
07:59AM  Starboard delivers special shareholder meeting request to Depomed at MarketWatch
07:45AM  Starboard Delivers Special Meeting Request to Depomed and Issues Letter to Depomed Shareholders PR Newswire
Sep-16-16 06:23PM  Why Avis Budget Group, Depomed, and Community Health Systems Jumped Today at Motley Fool +14.60%
05:17PM  Depomed Receives Request to Call Special Meeting of Shareholders GlobeNewswire
04:07PM  Stocks End Volatile Week With Fed Meeting in Focus
01:13PM  Why DepoMed's Shares Are Jumping 12% Today at Motley Fool
12:19PM  Stocks Hold Lower as Crude Oil Slides
11:25AM  40 Trading Lessons from The PlayBook
11:25AM  Calls look for more gains in Depomed
10:27AM  Depomed (DEPO) Stock Soars Amid Sale Speculation
09:27AM  Depomed Inc (DEPO), Oracle Corporation (ORCL) & More: Why These Stocks Are Making Headlines at Insider Monkey
08:58AM  The Market In 5 Minutes: A Down Week Comes To A Close
Sep-15-16 06:08PM  DepoMed shares jump on report drugmaker preparing sale at MarketWatch
Sep-13-16 02:55PM  More Rare Disease Dealmaking to Follow Horizon's Raptor Deal
11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
Sep-12-16 03:55PM  Activist Starboard demands rapid changes at Perrigo
Sep-08-16 01:22PM  Nektar And Three Other Momentum Stocks With Bullish Charts at Forbes
11:57AM  4 Breakout Stocks to Watch
08:00AM  Data from Depomeds Highly-Differentiated Pain and CNS-Focused Product Portfolio Presented at PAINWeek 2016 GlobeNewswire
Sep-07-16 08:00AM  Depomed to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire
Sep-06-16 08:00AM  Depomed Announces Presentations at PAINWeek 2016 GlobeNewswire
Aug-29-16 11:18AM  ETFs with exposure to Depomed, Inc. : August 29, 2016
Aug-26-16 08:16AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : August 26, 2016
Aug-17-16 01:21PM  Infoblox, Depomed, Insperity: Inside Starboard Values 5 Biggest Moves of Q2 at Insider Monkey
Aug-16-16 06:31PM  Why a hedge fund wants this East Bay drug company to run like Olive Garden at bizjournals.com
Aug-12-16 10:30AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-10-16 12:36PM  5 stocks to watch at MarketWatch
05:50AM  [$$] Drugmakers hooked on $10bn opioid habit at Financial Times
Aug-08-16 02:03PM  ETFs with exposure to Depomed, Inc. : August 8, 2016
Aug-05-16 08:08AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : August 5, 2016
Aug-04-16 01:22AM  Edited Transcript of DEPO earnings conference call or presentation 3-Aug-16 8:30pm GMT
Aug-03-16 05:35PM  Depomed reports 2Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:09PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Depomed Reports Second Quarter 2016 Financial Results GlobeNewswire
09:05AM  GlaxoSmithKlines Consumer Healthcare Grows in 2Q16
07:07AM  Q2 2016 Depomed Inc Earnings Release - After Market Close
Jul-27-16 04:05PM  Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 GlobeNewswire
Jul-26-16 09:13AM  Starboard Delivers Letter To Depomed Shareholders PR Newswire
Jul-18-16 01:34PM  Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent PR Newswire
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology; and Cebranopadol, a molecule for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moretti August JChief Financial Officer & SVPNov 14Option Exercise12.695,00063,45026,680Nov 15 04:43 PM
Moretti August JChief Financial Officer & SVPNov 14Sale20.845,000104,20021,680Nov 15 04:43 PM
Vargas Thadd MSenior VP, BDSep 21Sale25.0011,250281,25073,086Sep 22 06:11 PM
Moretti August JChief Financial Officer & SVPAug 10Option Exercise12.693,29741,83924,977Aug 11 05:01 PM
Moretti August JChief Financial Officer & SVPAug 10Sale21.405,000107,00021,680Aug 11 05:01 PM
Vargas Thadd MSenior VP, BDAug 10Sale20.9226,290549,98784,336Aug 11 04:56 PM
Vargas Thadd MSenior VP, BDMay 23Sale20.0015,000300,000109,297May 25 04:46 PM
Vargas Thadd MSenior VP, BDMay 10Sale17.6415,000264,600124,297May 10 05:14 PM
Moretti August JChief Financial Officer & SVPMay 09Sale18.005,00090,00022,879May 09 04:48 PM
Schoeneck James APresident and CEOMar 18Option Exercise3.9430,483120,09436,848Mar 21 04:17 PM
Vargas Thadd MSenior VP, BDMar 11Sale16.0023,000368,000137,737Mar 11 06:40 PM
Vargas Thadd MSVP, Business DevelopmentMar 02Sale15.1810,000151,780160,737Mar 04 08:28 PM
Vargas Thadd MSVP, Business DevelopmentJan 11Option Exercise7.1218,180129,442170,737Jan 12 07:10 PM
Schoeneck James APresident and CEODec 28Option Exercise6.116,36538,8906,365Dec 28 07:24 PM
Moretti August JChief Financial Officer & SVPDec 16Option Exercise5.355,00026,75026,319Dec 17 12:31 PM
Moretti August JChief Financial Officer & SVPDec 03Sale18.1115,000271,59721,319Dec 03 06:32 PM